Comparative Pharmacology
Head-to-head clinical analysis: ALTACE versus GRAFAPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTACE versus GRAFAPEX.
ALTACE vs GRAFAPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme inhibitor; inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion.
GRAFAPEX is a monoclonal antibody that binds to and inhibits the activity of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
2.5-5 mg orally once daily initially, titrated to 10-20 mg once daily; maximum 20 mg/day
10-20 mg orally once daily, maximum 40 mg per day.
None Documented
None Documented
Ramiprilat: 13–17 hours (prolonged in renal impairment, up to 50 hours in severe renal insufficiency; multiple doses: 45–60 hours effective half-life due to tissue binding)
Terminal elimination half-life: 12 hours (range 10-14 hours); clinical context: dosing interval recommended every 24 hours to maintain therapeutic levels
Renal: 60% (30% as ramiprilat, 30% as metabolites); Fecal: 40% (unabsorbed drug and biliary metabolites)
Renal: 60% as unchanged drug; biliary/fecal: 30%; minor metabolism: 10%
Category C
Category C
ACE Inhibitor
ACE Inhibitor